TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota test… Read more
TCI GENE Inc. (6879) - Total Assets
Latest total assets as of June 2025: NT$1.11 Billion TWD
Based on the latest financial reports, TCI GENE Inc. (6879) holds total assets worth NT$1.11 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TCI GENE Inc. - Total Assets Trend (2021–2024)
This chart illustrates how TCI GENE Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TCI GENE Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TCI GENE Inc.'s total assets of NT$1.11 Billion consist of 90.5% current assets and 9.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 9.0% |
| Accounts Receivable | NT$95.66 Million | 8.7% |
| Inventory | NT$43.87 Million | 4.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how TCI GENE Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TCI GENE Inc.'s current assets represent 90.5% of total assets in 2024, an increase from 86.8% in 2021.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2024, down from 58.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 8.7% of total assets.
TCI GENE Inc. Competitors by Total Assets
Key competitors of TCI GENE Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TCI GENE Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TCI GENE Inc. generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, TCI GENE Inc. generates $5.12 in net profit.
TCI GENE Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.74 | 7.14 | 7.14 |
| Quick Ratio | 5.56 | 6.78 | 6.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$830.10 Million | NT$ 968.72 Million | NT$ 968.72 Million |
TCI GENE Inc. - Advanced Valuation Insights
This section examines the relationship between TCI GENE Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.97 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | NT$1.10 Billion |
| Market Capitalization | $4.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values TCI GENE Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TCI GENE Inc.'s assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TCI GENE Inc. (2021–2024)
The table below shows the annual total assets of TCI GENE Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.10 Billion | -5.73% |
| 2023-12-31 | NT$1.17 Billion | +0.22% |
| 2022-12-31 | NT$1.16 Billion | +107.62% |
| 2021-12-31 | NT$560.31 Million | -- |